Maurits Brandt joined Novo Holdings in 2022 as a Senior Associate in Seed Investments.
Prior to Novo Holdings Maurits had a Business Development role in ProQR Therapeutics, a biotech company developing oligonucleotide based therapeutics. Here he was responsible for in- and outlicensing of various assets and technologies and aided in the internal business development. Prior to this, he was Senior Analyst at Aescap, a public equity investment fund with a focus on innovative therapeutics.
Maurits holds a BSc in Chemistry and an MSc in Molecular Biology, both from Leiden University.